Details
Stereochemistry | ACHIRAL |
Molecular Formula | C10H12N2O |
Molecular Weight | 176.2151 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NCCC1=CNC2=C1C=C(O)C=C2
InChI
InChIKey=QZAYGJVTTNCVMB-UHFFFAOYSA-N
InChI=1S/C10H12N2O/c11-4-3-7-6-12-10-2-1-8(13)5-9(7)10/h1-2,5-6,12-13H,3-4,11H2
Molecular Formula | C10H12N2O |
Molecular Weight | 176.2151 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Serotonin (5-hydroxytryptamine, or 5-HT) is a monoamine neurotransmitter produced by serotonergic neurons in the CNS and enterochromaffin cells in the gastrointestinal tract. Pharmacologic action of serotonin is mediated by a large and diverse range of 5-HT receptors. Serotonin plays an important part in the biochemistry of depression, migraine, bipolar disorder, and anxiety. It is also believed to be influential on sexuality and appetite. Creatinine is a product of the metabolic breakdown of creatine phosphate in muscle. Creatinine is filtered by healthy kidneys. Serotonin creatinine sulfate complex was the first isolated salt form of serotonin.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Actions of roxindole at recombinant human dopamine D2, D3 and D4 and serotonin 5-HT1A, 5-HT1B and 5-HT1D receptors. | 1999 Jun |
|
Effect of the 5-hydroxytryptamine3 (5-HT3)-receptor antagonist KB-R6933 on experimental diarrhea models. | 1999 May |
|
Serotonin in human allergic contact dermatitis. An immunohistochemical and high-performance liquid chromatographic study. | 1999 May |
|
Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. | 2000 Dec 5 |
|
Structure of the human serotonin 5-HT4 receptor gene and cloning of a novel 5-HT4 splice variant. | 2000 Feb |
|
Effect of GBR 12909 and fluoxetine on the acute and long term changes induced by MDMA ('ecstasy') on the 5-HT and dopamine concentrations in mouse brain. | 2001 |
|
Modulation of 5-HT(1A) receptor activation by its interaction with wild-type and mutant g(alphai3) proteins. | 2001 |
|
Interaction of serotonin 5-hydroxytryptamine type 2C receptors with PDZ10 of the multi-PDZ domain protein MUPP1. | 2001 Apr 20 |
|
Conversion of the ion selectivity of the 5-HT(3a) receptor from cationic to anionic reveals a conserved feature of the ligand-gated ion channel superfamily. | 2001 Apr 6 |
|
Identification of the aromatic L-amino acid decarboxylase (AADC) gene and its expression in the attachment and metamorphosis of the barnacle, Balanus amphitrite. | 2001 Feb |
|
Cisapride and dexamethasone in the prevention of delayed emesis after cisplatin administration. | 2001 Jan |
|
Trimethoprim-sulfamethoxazole and clozapine. | 2001 Jan |
|
Misdiagnosis of schizophrenia for a patient with epilepsy. | 2001 Jan |
|
Levels of serotonin receptor 2A higher in suicide victims? | 2001 Jan |
|
A novel augmentation strategy for treating resistant major depression. | 2001 Jan |
|
Ondansetron hydrochloride for the treatment of delirium after coronary artery surgery. | 2001 Jan |
|
Ondansetron is no more effective than supplemental intraoperative oxygen for prevention of postoperative nausea and vomiting. | 2001 Jan |
|
A single serotonergic modulatory cell can mediate reinforcement in the withdrawal network of the terrestrial snail. | 2001 Jan |
|
Melatonin potentiates contractile responses to serotonin in isolated porcine coronary arteries. | 2001 Jan |
|
Pharmacological agents for the treatment of urinary incontinence due to overactive bladder. | 2001 Jan |
|
Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. | 2001 Jan |
|
Effects of chronic antidepressant treatments on 5-HT and NA transporters in rat brain: an autoradiographic study. | 2001 Jan |
|
Necessity of thromboxane A2 for initiation of platelet-mediated contact sensitivity: dual activation of platelets and vascular endothelial cells. | 2001 Jan 1 |
|
Phenyl benzenesulfonamides are novel and selective 5-HT6 antagonists: identification of N-(2,5-dibromo-3-fluorophenyl)-4-methoxy-3-piperazin-1-ylbenzenesulfonamide (SB-357134). | 2001 Jan 8 |
|
Alcohol-induced euphoria: exclusion of serotonin. | 2001 Jan-Feb |
|
Pharmacological characterization of the rat paw edema induced by Bothrops lanceolatus (Fer de lance) venom. | 2001 Jun |
Patents
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:16:50 GMT 2023
by
admin
on
Fri Dec 15 15:16:50 GMT 2023
|
Record UNII |
333DO1RDJY
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LOINC |
14910-4
Created by
admin on Fri Dec 15 15:16:50 GMT 2023 , Edited by admin on Fri Dec 15 15:16:50 GMT 2023
|
||
|
NCI_THESAURUS |
C687
Created by
admin on Fri Dec 15 15:16:50 GMT 2023 , Edited by admin on Fri Dec 15 15:16:50 GMT 2023
|
||
|
LOINC |
2939-7
Created by
admin on Fri Dec 15 15:16:50 GMT 2023 , Edited by admin on Fri Dec 15 15:16:50 GMT 2023
|
||
|
DSLD |
4216 (Number of products:1)
Created by
admin on Fri Dec 15 15:16:50 GMT 2023 , Edited by admin on Fri Dec 15 15:16:50 GMT 2023
|
||
|
LOINC |
42671-8
Created by
admin on Fri Dec 15 15:16:50 GMT 2023 , Edited by admin on Fri Dec 15 15:16:50 GMT 2023
|
||
|
LOINC |
32339-4
Created by
admin on Fri Dec 15 15:16:50 GMT 2023 , Edited by admin on Fri Dec 15 15:16:50 GMT 2023
|
||
|
LOINC |
25524-0
Created by
admin on Fri Dec 15 15:16:50 GMT 2023 , Edited by admin on Fri Dec 15 15:16:50 GMT 2023
|
||
|
LOINC |
34373-1
Created by
admin on Fri Dec 15 15:16:50 GMT 2023 , Edited by admin on Fri Dec 15 15:16:50 GMT 2023
|
||
|
LOINC |
34374-9
Created by
admin on Fri Dec 15 15:16:50 GMT 2023 , Edited by admin on Fri Dec 15 15:16:50 GMT 2023
|
||
|
LOINC |
25981-2
Created by
admin on Fri Dec 15 15:16:50 GMT 2023 , Edited by admin on Fri Dec 15 15:16:50 GMT 2023
|
||
|
LOINC |
17003-5
Created by
admin on Fri Dec 15 15:16:50 GMT 2023 , Edited by admin on Fri Dec 15 15:16:50 GMT 2023
|
||
|
LOINC |
2940-5
Created by
admin on Fri Dec 15 15:16:50 GMT 2023 , Edited by admin on Fri Dec 15 15:16:50 GMT 2023
|
||
|
LOINC |
18375-6
Created by
admin on Fri Dec 15 15:16:50 GMT 2023 , Edited by admin on Fri Dec 15 15:16:50 GMT 2023
|
||
|
LOINC |
2941-3
Created by
admin on Fri Dec 15 15:16:50 GMT 2023 , Edited by admin on Fri Dec 15 15:16:50 GMT 2023
|
||
|
LOINC |
71804-9
Created by
admin on Fri Dec 15 15:16:50 GMT 2023 , Edited by admin on Fri Dec 15 15:16:50 GMT 2023
|
||
|
LOINC |
18253-5
Created by
admin on Fri Dec 15 15:16:50 GMT 2023 , Edited by admin on Fri Dec 15 15:16:50 GMT 2023
|
||
|
LOINC |
56978-0
Created by
admin on Fri Dec 15 15:16:50 GMT 2023 , Edited by admin on Fri Dec 15 15:16:50 GMT 2023
|
||
|
LOINC |
26035-6
Created by
admin on Fri Dec 15 15:16:50 GMT 2023 , Edited by admin on Fri Dec 15 15:16:50 GMT 2023
|
||
|
LOINC |
27057-9
Created by
admin on Fri Dec 15 15:16:50 GMT 2023 , Edited by admin on Fri Dec 15 15:16:50 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5202
Created by
admin on Fri Dec 15 15:16:50 GMT 2023 , Edited by admin on Fri Dec 15 15:16:50 GMT 2023
|
PRIMARY | |||
|
SEROTONIN
Created by
admin on Fri Dec 15 15:16:50 GMT 2023 , Edited by admin on Fri Dec 15 15:16:50 GMT 2023
|
PRIMARY | |||
|
100000078432
Created by
admin on Fri Dec 15 15:16:50 GMT 2023 , Edited by admin on Fri Dec 15 15:16:50 GMT 2023
|
PRIMARY | |||
|
350546
Created by
admin on Fri Dec 15 15:16:50 GMT 2023 , Edited by admin on Fri Dec 15 15:16:50 GMT 2023
|
PRIMARY | |||
|
C828
Created by
admin on Fri Dec 15 15:16:50 GMT 2023 , Edited by admin on Fri Dec 15 15:16:50 GMT 2023
|
PRIMARY | |||
|
m9871
Created by
admin on Fri Dec 15 15:16:50 GMT 2023 , Edited by admin on Fri Dec 15 15:16:50 GMT 2023
|
PRIMARY | Merck Index | ||
|
200-058-9
Created by
admin on Fri Dec 15 15:16:50 GMT 2023 , Edited by admin on Fri Dec 15 15:16:50 GMT 2023
|
PRIMARY | |||
|
D012701
Created by
admin on Fri Dec 15 15:16:50 GMT 2023 , Edited by admin on Fri Dec 15 15:16:50 GMT 2023
|
PRIMARY | |||
|
28790
Created by
admin on Fri Dec 15 15:16:50 GMT 2023 , Edited by admin on Fri Dec 15 15:16:50 GMT 2023
|
PRIMARY | |||
|
50-67-9
Created by
admin on Fri Dec 15 15:16:50 GMT 2023 , Edited by admin on Fri Dec 15 15:16:50 GMT 2023
|
PRIMARY | |||
|
1311214
Created by
admin on Fri Dec 15 15:16:50 GMT 2023 , Edited by admin on Fri Dec 15 15:16:50 GMT 2023
|
PRIMARY | RxNorm | ||
|
DTXSID8075330
Created by
admin on Fri Dec 15 15:16:50 GMT 2023 , Edited by admin on Fri Dec 15 15:16:50 GMT 2023
|
PRIMARY | |||
|
DB08839
Created by
admin on Fri Dec 15 15:16:50 GMT 2023 , Edited by admin on Fri Dec 15 15:16:50 GMT 2023
|
PRIMARY | |||
|
333DO1RDJY
Created by
admin on Fri Dec 15 15:16:50 GMT 2023 , Edited by admin on Fri Dec 15 15:16:50 GMT 2023
|
PRIMARY | |||
|
333DO1RDJY
Created by
admin on Fri Dec 15 15:16:50 GMT 2023 , Edited by admin on Fri Dec 15 15:16:50 GMT 2023
|
PRIMARY | |||
|
SUB15230MIG
Created by
admin on Fri Dec 15 15:16:50 GMT 2023 , Edited by admin on Fri Dec 15 15:16:50 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST |
IC50
|
||
|
TRANSPORTER -> SUBSTRATE |
|
||
|
TARGET -> AGONIST |
BINDING
IC50
|
||
|
TARGET -> AGONIST |
BINDING
IC50
|
||
|
TARGET -> INHIBITOR |
BINDING
IC50
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
ACTIVATOR OF RELEASE->TARGET |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> AGONIST |
AGONIST
|
||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
||
|
PARENT -> METABOLITE ACTIVE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|